🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Addus HomeCare Corporation ADUS R2KR3KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.addus.com
Company Profile ↓
$118.76
+2.09% 1Y
Mkt Cap$2.22B
P/E20.80
P/B1.91
52W High$122.75
52W Low$88.49
Book Value$62.77
EPS (TTM)$5.71

Company Overview

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. Its Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. Its Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company serves federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 24.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 17.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 20.8, below the sector median of 25.2.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.42B (+23.2% YoY); net profit $95.91M.
  • Trailing 12 Months Year-on-year growth — revenue +8.0%, earnings +24.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 17.2%, profit CAGR 24.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:17.15%
1 Year:8.00%

Compounded Profit Growth

5 Years:24.46%
1 Year:24.20%

Stock Price Performance

1 Year:+2.09%
6 Months:+15.07%
3 Months:+28.95%
1 Month:-0.02%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
$88.49 $122.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)56.12 · Neutral
Price Performance
1M-0.02%
3M+28.95%
6M+15.07%
1Y+2.09%
Valuation vs Sector

P/E of 20.80 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 17.2% over 5 years.
  • Profit CAGR of 24.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.80
Industry PE
25.17
Forward P/E
15.83
PEG Ratio
1.12
Book Value
$62.77
Price to Book
1.91
P/S
1.51
EV/EBITDA
13.23
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
17.15%
Profit 5Y
24.46%
Revenue (YoY)
8.00%
Earnings (YoY)
24.20%

Profitability & Returns

ROCE
10.76%
ROE
9.71%
ROA
6.52%
Profit Margin
7.13%
Op Margin
10.32%
Gross Margin
32.36%
EPS (Latest Qtr)
$1.49
EPS (TTM)
$5.71

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
1.46
Current Ratio
1.69
Debt
$108.82M
Total Assets
$1.46B
Current Assets
$272.88M
Working Capital
$120.00M

Ownership

Promoter Holding
2.81%
Chg in Prom Hold
-0.00%
FII / Inst Holding
107.96%
Chg in FII Hold
-0.03%

Financial Snapshot

Enterprise Value
$2.22B
Total Revenue (TTM)
$1.48B
EBITDA
$166.14M
Free Cash Flow
$119.75M
Operating Cash Flow
$162.40M
Shares Outstanding
18.66M
Gross Margin
32.36%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADUS Addus HomeCare Corporation R2KR3KPHARMA 118.76 20.80 $2.22B 0.00% 10.76% 9.71% 17.15% 24.46%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------101.67M103.63M108.66M112.03M109.13M130.89M137.34M139.29M138.51M148.91M168.99M192.38M190.22M184.58M193.99M196.00M205.30M217.89M216.66M226.63M236.94M240.50M251.60M259.98M270.72M280.75M286.92M289.79M337.71M349.44M362.30M373.08M363.61M377.42M
Cost of Revenue ----------------------------------230.03M235.57M245.59M249.47M247.74M-
Gross Profit 23.52M22.19M24.32M25.70M27.42M28.66M27.39M28.58M29.12M30.79M27.58M35.38M36.41M37.43M36.83M39.69M45.18M57.54M55.84M55.00M56.30M59.10M61.20M68.81M67.05M70.19M75.60M75.19M78.42M82.32M86.73M88.18M93.16M92.20M107.68M113.88M116.72M123.61M115.87M121.56M
Operating Expenses ----------------------------------77.16M80.99M83.78M81.33M81.80M-
Operating Income 4.28M3.02M653.00K4.39M2.50M7.69M7.03M5.99M5.88M7.47M4.24M6.55M5.61M6.43M5.50M7.39M7.33M14.53M10.66M9.61M12.52M11.72M12.17M17.05M17.36M13.51M16.89M17.52M18.61M21.54M22.84M23.64M26.18M25.95M30.51M32.89M32.94M42.28M34.07M38.94M
EBITDA ----------------------------------34.96M37.38M38.10M47.02M38.61M-
Interest Expense ----------------------------------4.02M3.52M3.34M2.73M2.15M-
Pretax Income ----------------------------------27.00M29.95M30.35M40.15M32.43M-
Tax Provision ----------------------------------5.77M7.89M7.51M10.37M7.36M-
Net Income 2.89M3.32M157.00K2.60M1.70M7.57M4.31M2.76M3.46M3.15M4.63M4.05M3.36M4.39M4.30M5.29M4.91M10.74M8.66M6.91M9.12M8.45M8.89M11.60M11.58M8.47M11.25M11.54M12.68M14.85M15.41M15.83M18.08M20.16M21.23M22.05M22.85M29.78M25.07M27.61M
Diluted EPS 0.260.290.010.230.150.660.370.240.290.270.400.340.270.330.320.390.350.680.540.430.570.530.550.720.720.530.700.710.780.910.950.971.101.101.151.201.241.611.341.49

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------400.93M425.99M516.65M648.79M764.77M-951.12M1.06B1.15B1.42B
Cost of Revenue -------------651.38M718.77M779.58M960.66M
Gross Profit 76.61M59.72M61.47M64.05M67.74M83.73M91.32M106.34M115.88M136.80M179.24M226.24M-299.74M339.88M375.02M461.87M
Operating Expenses -------------231.00M248.92M272.33M323.26M
Operating Income 11.78M9.27M12.92M15.66M15.46M18.07M16.02M15.48M25.25M22.83M34.75M44.51M-68.74M90.96M102.69M138.62M
EBITDA -------------83.14M106.56M120.61M157.47M
Interest Expense -------------8.91M11.11M7.73M13.61M
Pretax Income -------------60.17M81.33M99.35M127.44M
Tax Provision -------------14.15M18.81M25.75M31.54M
Net Income 3.60M6.03M-1.98M7.63M19.14M12.24M11.62M12.16M11.95M16.43M25.24M33.13M-46.02M62.52M73.60M95.91M
Diluted EPS ---0.180.711.731.101.041.071.031.331.772.08-2.843.834.065.18

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --166.92M154.69M149.86M163.93M180.80M185.80M229.86M271.69M348.09M636.75M892.58M-937.99M1.02B1.41B1.44B
Current Assets --------------222.81M200.00M260.38M269.49M
Cash & Equivalents 6.11M518.00K816.00K2.02M1.74M15.56M13.36M4.10M8.01M53.75M70.41M111.71M145.08M-79.96M64.79M98.91M81.62M
Inventory ------------------
Receivables --------------125.50M115.50M122.88M151.69M
Total Liabilities --78.83M68.25M55.44M50.08M52.85M44.07M72.10M95.38M79.60M161.16M373.91M-304.45M317.73M442.14M352.00M
Current Liabilities --37.13M43.29M39.19M45.54M43.20M42.19M49.62M55.08M61.50M87.53M143.90M-131.15M145.12M155.87M149.49M
Long Term Debt --40.03M24.96M16.25M--1.88M22.48M39.86M17.22M59.16M193.90M-131.77M124.13M218.44M120.96M
Total Debt --------------178.05M175.18M273.13M171.36M
Total Equity 34.58M80.57M88.09M86.44M94.42M113.86M126.79M141.58M154.67M170.34M268.49M475.59M518.68M-633.54M706.69M970.49M1.09B
Shares Outstanding --------------16.13M16.23M18.15M18.52M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.93M10.70M15.95M15.40M27.39M-4.11M-743.00K52.77M33.20M12.02M109.41M-105.11M112.25M116.43M111.51M
Investing Cash Flow -14.85M-6.20M-1.05M-619.00K2.89M--10.72M-21.74M-24.27M-67.79M-188.70M-214.24M--106.59M-119.24M-354.61M-32.50M
Financing Cash Flow 18.18M-4.21M-13.69M-15.07M-16.46M--2.64M26.39M17.24M51.24M217.99M138.19M--87.45M-8.18M272.30M-96.30M
Capital Expenditure -671.00K-612.00K-551.00K-1.11M-887.00K-5.27M-2.21M-1.71M-3.62M-5.35M-4.62M-6.83M--8.30M-9.45M-6.05M-7.72M
Free Cash Flow -9.60M10.09M15.40M14.29M26.51M-1.89M-2.46M49.16M27.85M7.40M102.58M-96.81M102.79M110.38M103.79M
Net Change in Cash --------------88.93M-15.17M34.12M-17.29M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------26.5%27.2%26.5%27.6%29.6%-31.5%32.1%32.5%32.5%
Operating Margin % -------3.9%5.9%4.4%5.4%5.8%-7.2%8.6%8.9%9.7%
Net Margin % -------3.0%2.8%3.2%3.9%4.3%-4.8%5.9%6.4%6.7%
ROE % 4.5%6.8%-2.3%8.1%16.8%9.7%8.2%7.9%7.0%6.1%5.3%6.4%-7.3%8.8%7.6%8.8%
ROCE % -7.1%11.6%14.2%13.1%13.1%11.2%8.6%11.7%8.0%6.3%5.9%-8.5%10.3%8.2%10.8%

Shareholding Pattern

Insiders
2.81%
Institutions
107.96%
Public Float
111.09%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 18.34% 3.43M $395.81M
2 Capital Research Global Investors 7.44% 1.39M $160.60M
3 Dimensional Fund Advisors LP 4.47% 835.16K $96.50M
4 Vanguard Capital Management LLC 4.23% 789.33K $91.21M
5 State Street Corporation 4.17% 777.83K $89.88M
6 Silvercrest Asset Management Group, LLC 3.70% 691.25K $79.87M
7 Wasatch Advisors LP 3.65% 680.93K $78.68M
8 American Century Companies Inc 3.02% 564.64K $65.24M
9 Geode Capital Management, LLC 2.76% 515.52K $59.57M
10 Principal Financial Group, Inc. 2.20% 411.56K $47.56M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADUS

Yahoo Finance hu, 03 Sep 2026

1 Growth Stock to Stash and 2 We Turn Down

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when traject…

Yahoo Finance Fri, 28 Aug 2026

Is Addus HomeCare (ADUS) Undervalued After Its Q2 Earnings Beat?

Addus HomeCare Q2 results and what they mean for the stock Addus HomeCare (ADUS) drew attention after reporting Q2 2026 results that showed revenue in line with expectations alongside an earnings per share beat. For investors, that mix rais…

Yahoo Finance Fri, 28 Aug 2026

Addus HomeCare (ADUS) Stock Looks Cheap Relative To Fair Value

Addus HomeCare stock has delivered a 34.6% gain over the past three years, while a fresh intrinsic value estimate suggests the current price may still sit below what its future cash flows imply. The market price near US$118 puts investors b…

Yahoo Finance Wed, 26 Aug 2026

3 Reasons to Avoid ADUS and 1 Stock to Buy Instead

Over the past six months, Addus HomeCare has been a great trade, beating the S&P 500 by 5.7%. Its stock price has climbed to $121.14, representing a healthy 16.5% increase. This performance may have investors wondering how to approach the s…

Yahoo Finance ue, 25 Aug 2026

Are Options Traders Betting on a Big Move in Addus HomeCare Stock?

Investors need to pay close attention to ADUS stock based on the movements in the options market lately.

Yahoo Finance Wed, 12 Aug 2026

Addus HomeCare (ADUS) Just Flashed Golden Cross Signal: Do You Buy?

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

ADUS — Frequently Asked Questions

What is the current share price of Addus HomeCare Corporation (ADUS)?

As of 2026-09-07 16:24 PDT, Addus HomeCare Corporation (ADUS) trades at $118.76 on NasdaqGS. Its 52-week range is $88.49 to $122.75.

What is the market capitalisation of ADUS?

Addus HomeCare Corporation (ADUS) has a market capitalisation of $2.22B on NasdaqGS.

What is the P/E ratio of ADUS?

ADUS trades at a trailing price-to-earnings (P/E) ratio of 20.80. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.91.

What is the return on equity (ROE) of ADUS?

ADUS has a return on equity (ROE) of 9.71%. Its return on capital employed (ROCE) is 10.76%.

Is ADUS a good stock to buy?

This page provides a data-driven analysis of Addus HomeCare Corporation (ADUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space